4//SEC Filing
LOUMEAU ERIC J 4
Accession 0001239648-26-000004
CIK 0001370053other
Filed
Jan 7, 7:00 PM ET
Accepted
Jan 8, 4:12 PM ET
Size
19.7 KB
Accession
0001239648-26-000004
Insider Transaction Report
Form 4
ANAPTYSBIO, INCANAB
LOUMEAU ERIC J
CHIEF LEGAL OFFICER
Transactions
- Exercise/Conversion
Common Stock
2026-01-06+5,545→ 18,796 total - Sale
Common Stock
2026-01-07$45.11/sh−2,017$90,987→ 16,779 total - Sale
Common Stock
2026-01-07$45.38/sh−5,281$239,672→ 11,498 total - Sale
Common Stock
2026-01-07$46.13/sh−1,841$84,926→ 9,657 total - Sale
Common Stock
2026-01-07$47.23/sh−500$23,615→ 9,157 total - Exercise/Conversion
Restricted Stock Unit
2026-01-06−5,545→ 5,545 total→ Common Stock (5,545 underlying) - Award
Restricted Stock Unit
2026-01-06+17,100→ 17,100 total→ Common Stock (17,100 underlying) - Award
Stock Option (right to buy)
2026-01-06+23,200→ 23,200 totalExercise: $43.91Exp: 2036-01-05→ Common Stock (23,200 underlying)
Footnotes (8)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
- [F2]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F3]The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated April 11, 2025.
- [F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.87 to $45.835 per share, inclusive. The reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.96 to $46.83 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- [F7]The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- [F8]The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Documents
Issuer
ANAPTYSBIO, INC
CIK 0001370053
Entity typeother
Related Parties
1- filerCIK 0001239648
Filing Metadata
- Form type
- 4
- Filed
- Jan 7, 7:00 PM ET
- Accepted
- Jan 8, 4:12 PM ET
- Size
- 19.7 KB